about
The burgeoning HIV/HCV syndemic in the urban Northeast: HCV, HIV, and HIV/HCV coinfection in an urban settingAlcoholic liver disease and hepatitis C: a frequently underestimated combinationHigh prevalence and genetic diversity of HCV among HIV-1 infected people from various high-risk groups in ChinaInfectious disease comorbidities adversely affecting substance users with HIV: hepatitis C and tuberculosis.Interaction between innate immunity and porcine reproductive and respiratory syndrome virus.[Consensus methods: review of original methods and their main alternatives used in public health].Hepatitis C seropositivity and kidney function decline among women with HIV: data from the Women's Interagency HIV Study.Hepatitis C treatment experiences and decision making among patients living with HIV infection.CD127 expression, exhaustion status and antigen specific proliferation predict sustained virologic response to IFN in HCV/HIV co-infected individuals.Comparison of HCV viral load and its genotype distributions in HCV mono- and HIV/HCV co-infected illicit drug usersProteomic analysis of serum and urine of HIV-monoinfected and HIV/HCV-coinfected patients undergoing long term treatment with nevirapine.The relation of HLA genotype to hepatitis C viral load and markers of liver fibrosis in HIV-infected and HIV-uninfected womenHost Genetic Factors and Dendritic Cell Responses Associated with the Outcome of Interferon/Ribavirin Treatment in HIV-1/HCV Co-Infected Individuals.Lower ribavirin biodisponibility in patients with HIV-HCV coinfection in comparison with HCV monoinfected patients.Prevalence and correlates of HCV monoinfection and HIV and HCV coinfection among persons who inject drugs in Vietnam.HCV/ HIV co-infection: time to re-evaluate the role of HIV in the liver?12 Weeks of Daclatasvir in Combination With Sofosbuvir for HIV-HCV Coinfection (ALLY-2 Study): Efficacy and Safety by HIV Combination Antiretroviral Regimens.Reduced healthcare utilization following successful hepatitis C virus treatment in HIV-co-infected patients with mild liver diseaseSafely treating hepatitis C in patients with HIV or hepatitis B virus coinfection.Predicting Discontinuation of Pegylated Interferon as a Result of Lack of Efficacy in United States Veterans With Chronic Hepatitis C on Dual Therapy.Sorafenib therapy for hepatocellular carcinoma in an HIV-HCV coinfected patient: a case report.Adjuvant high-dose interferon-{alpha} for resected melanoma in a patient with HIV infection.Dominant enrichment of phenotypically activated CD38(+) HLA-DR(+) CD8(+) T cells, rather than CD38(+) HLA-DR(+) CD4(+) T cells, in HIV/HCV coinfected patients on antiretroviral therapy.Impact of HIV infection in patients infected with chronic HCV (genotypes 1a and 3a): virological and clinical changes.Epidemiological distribution and genotype characterization of hepatitis C virus and HIV co-infection in Wuhan, China, where the prevalence of HIV is low.Clinical and histological characteristics of HIV and hepatitis C virus-co-infected patients in Brazil: a case series study.Different distributions of hepatitis C virus genotypes among HIV-infected patients with acute and chronic hepatitis C according to interleukin-28B genotype.Challenges in the treatment of chronic hepatitis C in the HIV/HCV-coinfected patient.Correlates of poor perceived health among individuals living with HIV and HBV chronic infections: a longitudinal assessment
P2860
Q21559628-177894DC-FA6D-42CF-B3A6-40B05C3AB55EQ22305502-86D11DF6-D0DD-4559-AC07-4C428D62D963Q28474105-F0BD28D8-05D6-46B2-85DF-0CCFD923F783Q30395708-D1275D5E-7603-4F18-B7CC-9C5522A6B359Q30410415-2679E0BD-69F7-4C73-A8AA-E10A1767E1CCQ33384750-6B23FA7C-ECE5-4295-9D27-E8C31BF91A40Q33435099-8685C253-7F9C-455A-801F-D773D9231A17Q33636377-DFD17C1E-86EB-47F5-A3C3-DECBB1EE7604Q33874737-5B09BA2E-1B76-45C4-9F47-B133AED1F8B3Q33893645-42187D9B-205A-4BF1-AAA9-26E79CF1741FQ34794696-FDED8A3D-C0BA-4D6C-803E-62E9D8903264Q35000910-F08D74FF-7A21-4431-BDBD-29F16F5AEC67Q35095654-40364D68-7A7D-4558-BA06-1B06827942E7Q35125818-0D19CA24-5644-4BB4-9732-B6168708C70AQ35235877-0860EA9B-5633-438F-AAF3-DCE0C95B2FCDQ36479368-29B15A81-1119-401D-BE16-14C19C513A24Q36948115-54185E0B-7317-4E57-A92B-05E6FCE0C61BQ37046208-989ECC64-5A23-4F04-AD1E-E045CD449C47Q38392453-0372B941-F064-44D7-8076-6517529C30CBQ39204755-F1675BAF-A52B-4E65-B8D5-3DA515E7E6BFQ39506117-9611DAE1-D811-4028-A4F4-2557BC2F110DQ39508180-3F43D9F7-DD5F-41CA-898E-42E64DF42334Q40109601-A5114DC0-72DE-4CBA-8DEE-A560DC7FF57EQ40457693-B8C09C77-430F-4FA6-B969-5B0E5C6D2B7FQ42282840-B9CE7983-5E67-4F5B-89BD-9EF3F9F220EFQ42981789-C0B42D56-04C3-4F21-8A2A-A51E2FB3C2A1Q43034902-565ECD30-A224-4659-A2C6-F3440822728DQ44369266-5533CDA3-01A2-4E7B-9C02-345C61062483Q58106560-B1F36AD0-7AFD-4D92-921E-11BBC88ED71E
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Therapeutic issues in HIV/HCV-coinfected patients
@ast
Therapeutic issues in HIV/HCV-coinfected patients
@en
Therapeutic issues in HIV/HCV-coinfected patients
@nl
type
label
Therapeutic issues in HIV/HCV-coinfected patients
@ast
Therapeutic issues in HIV/HCV-coinfected patients
@en
Therapeutic issues in HIV/HCV-coinfected patients
@nl
prefLabel
Therapeutic issues in HIV/HCV-coinfected patients
@ast
Therapeutic issues in HIV/HCV-coinfected patients
@en
Therapeutic issues in HIV/HCV-coinfected patients
@nl
P2860
P921
P3181
P1476
Therapeutic issues in HIV/HCV-coinfected patients
@en
P2093
M S Sulkowski
Y Benhamou
P2860
P304
P3181
P356
10.1111/J.1365-2893.2006.00816.X
P577
2007-06-01T00:00:00Z